The strong revenue growth and margin expansion signal improving commercial traction for OneTest, but the absolute revenue base remains tiny ($0.7M/quarter). Traders should watch for follow-through on the $1.0M+ expected from state firefighter programs and any news on the second state program. The standstill agreement with Streeterville reduces near-term dilution risk, but the company still has a $40M preferred facility that could be drawn.
Price Chart
Executive Summary
20/20 BioLabs reported Q2 2026 revenue of $0.7M (+36.5% YoY), driven by a record quarter for its OneTest MCED cancer screening test. Gross margin expanded to 41.7% from 30.5%, and the company eliminated all convertible note debt, ending the quarter with $4.5M in cash. However, the net loss widened to $1.5M from $0.8M, and the company remains pre-profitable with a $7M market cap, making the absolute revenue scale still very small.
Key Financial Metrics
Key Facts
- Total revenue increased 36.5% YoY to $0.7M for Q2 2026.
- OneTest revenue grew 47.1% YoY to $0.7M, representing 95.3% of total revenue.
- Gross margin expanded to 41.7% from 30.5% in the prior year period.
- Net loss was $1.5M for Q2 2026, compared to $0.8M in Q2 2025.
- Cash and cash equivalents totaled $4.5M as of June 30, 2026, up from $1.0M at year-end 2025.
- All convertible note debt was eliminated during the quarter.
- State-funded firefighter programs in Maryland and Vermont are expected to generate more than $1.0M of revenue through the end of 2026.
- The company entered into a 120-day standstill agreement with Streeterville, limiting conversion of Series E preferred stock.
Financial Impact
Revenue grew 36.5% YoY to $730,571; gross profit increased 86.6% to $304,727; net loss widened to $1,506,343 from $840,933.
Risk Factors
- Very small revenue base ($0.7M/quarter) with a $7M market cap makes the stock highly volatile.
- Net loss is widening ($1.5M vs $0.8M) and operating cash flow was negative $1.9M in H1 2026.
- The company relies on state-funded firefighter programs for growth, which may not be recurring.
- Series E preferred stock has a liquidation preference of $6.3M and can be converted into common stock, creating overhang.
- No analyst consensus estimates were available for comparison, making surprise magnitude unclear.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-090746 |
| Document: ea0302153-8k_2020bio.htm | 0001213900-26-090746 |
| Document: 0001213900-26-090746-index-headers.html | 0001213900-26-090746 |
| Document: 0001213900-26-090746-index.html | 0001213900-26-090746 |
| Document: 0001213900-26-090746.txt | 0001213900-26-090746 |
| 8-K Data (Synthetic) | 0001213900-26-090746 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | DEFA14A | $0.2507 | awaiting T+5 | — | $0.2400 (−4.27%) |
Oct 21, 2026 5d ago | DEF 14A | $0.2507 | awaiting T+5 | — | $0.2400 (−4.27%) |
Aug 17, 2026 10w ago | 8-K | $0.5200 $0.5282 | ▲ +1.58% | ▲ +1.78% | $0.2400 (−53.85%) |
Aug 17, 2026 10w ago | Press Release | $0.5503 $0.5182 | ▼ −5.83% | ▼ −4.64% | $0.2400 (−56.39%) |
Aug 5, 2026 11w ago | 8-K | $0.4413 $0.4610 | ▲ +4.46% | ▲ +4.11% | $0.2400 (−45.62%) |
Jul 1, 2026 16w ago | 8-K | $0.6095 $0.5851 | ▼ −4.00% | ▼ −4.26% | $0.2400 (−60.62%) |
Jun 23, 2026 17w ago | DEFA14A | $0.5669 $0.6095 | ▼ −7.51% | ▼ −5.81% | $0.2400 (+57.66%) |
May 26, 2026 21w ago | 8-K | $0.9700 $0.8400 | ▼ −13.40% | ▼ −13.87% | $0.2400 (−75.26%) |
May 20, 2026 22w ago | 8-K | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2400 (+80.17%) |
May 20, 2026 22w ago | Press Release | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2400 (+80.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers